CHD/Prevention News

A polypill containing multiple blood pressure-lowering drugs may be an effective solution to addressing both uncontrolled hypertension and polypharmacy causing non-adherence to antihypertensive medications, speakers reported.

The timing of when a patient takes their blood pressure medication does not appear to matter for reducing CV event risk, according to two trials and a meta-analysis presented at the European Society of Cardiology Congress.

In an analysis of deaths of patients with obesity but not diabetes from the SELECT trial, those assigned semaglutide 2.4 mg had reduced risk for death from COVID-19 compared with those assigned placebo.

Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.

Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study.

Among patients admitted to the cardiac ICU, those engaging in recreational drug use were almost three times as likely to experience a repeat serious CV event within 1 year compared with nonusers, researchers reported.

Systemic immune-inflammation index levels may be used to predict all-cause and cardiovascular mortality among patients with rheumatoid arthritis, according to data published in Scientific Reports.

GLP-1 receptor agonist use on top of SGLT2 inhibition in patients with HF with preserved ejection fraction, type 2 diabetes and obesity was associated with reduced risk for adverse events vs. SGLT2 inhibition alone, researchers reported.

Adults with obesity who have been prescribed tirzepatide can now purchase 2.5 mg and 5 mg single-dose vials of the medication, Eli Lilly announced.

Adults assigned to an evening of binge drinking alcohol experienced elevations in heart rate and sympathetic transduction to blood pressure the following morning, researchers reported.